Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation | Zendy

Shinsuke Miyazaki | Zendy; Taishi Kuwahara | Zendy; A. Kobori | Zendy; Yoshihide Takahashi | Zendy; Atsushi Takei | Zendy; Akira Sato | Zendy; Mitsuaki Isobe | Zendy; Atsushi Takahashi | Zendy

Open Access

Pharmacological cardioversion preceding left atrial ablation: bepridil predicts the clinical outcome following ablation in patients with persistent atrial fibrillation

Author(s) -

Shinsuke Miyazaki,

Taishi Kuwahara,

A. Kobori,

Yoshihide Takahashi,

Atsushi Takei,

Akira Sato,

Mitsuaki Isobe,

Atsushi Takahashi

Publication year - 2009

Publication title -

ep europace

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.119

H-Index - 102

eISSN - 1532-2092

pISSN - 1099-5129

DOI - 10.1093/europace/eup363

Subject(s) - bepridil , medicine , atrial fibrillation , ablation , sinus rhythm , cardiology , cardioversion , catheter ablation , pulmonary vein , anesthesia , surgery , calcium , verapamil

Bepridil is highly effective in terminating persistent atrial fibrillation (AF). Despite continued treatment, a high rate of AF recurrence after pharmacological cardioversion (PC) with bepridil has been reported. Bepridil therapy is also associated with significant adverse effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog